Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374696 | 0.92 | FOLH1 (0.61) | FOLH1HPGDGAALMNAL3MBTL1 | |
| SCHEMBL8768476 | 0.90 | FOLH1 (0.59) | FOLH1HPGDGAALMNAL3MBTL1 | |
| SCHEMBL6043201 | 0.90 | FOLH1 (0.59) | FOLH1HPGDGAALMNAL3MBTL1 | |
| Hexanoate SCHEMBL27879322 | 0.85 | AKR1B1 (0.50) | ALDH1A1ALOX15TSHRHSD17B10KDM4E | |
| Succinic Acid SCHEMBL29896371 | 0.85 | HPGD (0.49) | HPGDGAALMNAL3MBTL1ALDH1A1 | |
| Terephthalic Acid SCHEMBL27748404 | 0.84 | TSHR (0.68) | FOLH1HPGDGAALMNAL3MBTL1 | |
| Phthalic Acid SCHEMBL125858 | 0.83 | ALDH1A1 (0.74) | HPGDGAAALDH1A1ALOX15HSD17B10 | |
| Phthalic Acid SCHEMBL22217134 | 0.83 | ALDH1A1 (0.74) | HPGDGAAALDH1A1ALOX15HSD17B10 | |
| Toluene SCHEMBL27935612 | 0.82 | FOLH1 (0.52) | FOLH1HPGDGAALMNAL3MBTL1 | |
| SCHEMBL29062 | 0.82 | FOLH1 (0.66) | FOLH1HPGDLMNAALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050186572-A1 | Polymerase extension at 3' terminus of PNA-DNA chimera | EGHOLM MICHAEL (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1198594-B1 | POLYMERASE EXTENSION AT 3' TERMINUS OF PNA-DNA CHIMERA | APPLERA CORP (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1220953-B1 | TEMPLATE-DEPENDENT LIGATION WITH PNA-DNA CHIMERIC PROBES | APPLERA CORP (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030082558-A1 | Polymerase extension at 3' terminus of PNA-DNA chimera | PE CORPORATION (NY) | 2003-05-01 | — | — | US | disclosed |
| US-20020177133-A1 | Template-dependent ligation with PNA-DNA chimeric probes | APPLERA CORPORATION. | 2002-11-28 | — | — | US | disclosed |
| US-6469151-B1 | IMMOBILIZED ON SOLID SUBSTRATE; USE IN OLIGONUCLEOTIDE-LIGATION ASSAYS (OLA) AND SINGLE NUCLEOTIDE POLYMORPHISM DETECTION | PE CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-1220953-A2 | TEMPLATE-DEPENDENT LIGATION WITH PNA-DNA CHIMERIC PROBES | Applera Corporation (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1198594-A2 | POLYMERASE EXTENSION AT 3' TERMINUS OF PNA-DNA CHIMERA | Applera Corporation (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6316230-B1 | ENZYMATICALLY EXTENDING A PNA(PEPTIDE NUCLEIC ACID)-DNA CHIMERA IN PRESENCE OF TEMPLATE NUCLEIC ACID, POLYMERASE AND PRIMER EXTENSION REAGENT | APPLERA CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6297016-B1 | ENZYMATICALLY LIGATING A PEPTIDE NUCLEIC ACID-DNA CHIMERIC PROBE TO SECOND PROBE WHEN PROBES ARE HYBRIDIZED ADJACENT TO EACH OTHER ON A TEMPLATE NUCLEIC ACID | APPLERA CORPORATION | 2001-10-02 | — | — | US | disclosed |
| WO-2001027326-A2 | TEMPLATE-DEPENDENT LIGATION WITH PNA-DNA CHIMERIC PROBES | APPLERA CORPORATION (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001012852-A2 | POLYMERASE EXTENSION AT 3' TERMINUS OF PNA-DNA CHIMERA | APPLERA CORPORATION (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050186572-A1 | Polymerase extension at 3' terminus of PNA-DNA chimera | RNGTT, DNTT, POLL | FOLH1 1049/4885HPGD 2445/4885GAA 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.